Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Objective Response Rate (ORR)”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)UnknownNCT05582109
What this trial is testing

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Who this might be right for
Objective Response Rate (ORR)
Tianjin Medical University Cancer Institute and Hospital 30
Large-scale testing (Phase 3)Looking for participantsNCT06520345
What this trial is testing

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 520
Testing effectiveness (Phase 2)Study completedNCT01915589
What this trial is testing

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 16
Not applicableUnknownNCT03336554
What this trial is testing

Epigenetic Biomarker for Osteosarcoma

Who this might be right for
Histologic Response (Tumor Necrosis Rate)Objective Response Rate for Neoadjuvant Chemotherapy, ORRProgression-free Survival, PFS+1 more
Peking University People's Hospital 100
Testing effectiveness (Phase 2)Study completedNCT01915602
What this trial is testing

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 14
Testing effectiveness (Phase 2)Study completedNCT04815720
What this trial is testing

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Vaccinex Inc. 49
Not applicableStudy completedNCT05673967
What this trial is testing

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 62